Key Highlights

  • Shares rose 14.36% to USD 5.38 in regular trading on November 3, 2026, a gain of USD 0.6756.
  • Volume was only about 12,400 shares per the screen, which points to thin trading.
  • The proposed Merger with Vesicor Therapeutics, Inc. carries an Equity value of USD 70 million.
  • About USD 22.7 million remained in the trust account after the July 2025 redemptions.
  • The extended deadline to complete a Business combination is December 22, 2026.

What Moved Black Hawk Acquisition Today (up USD 0.6756, 14.36%)

Black Hawk Acquisition Corporation (NASDAQ:BKHA) rose 14.36% to USD 5.38 in regular trading on November 3, 2026, against the Monday, November 2 close of about USD 4.70 (calculated). The screen showed Volume of 12.4K shares and a Market Capitalisation of about USD 22.33 million.

No company announcement dated November 2 or November 3, 2026 was identified. With so few shares changing hands, a small number of orders can move the price, and the gain may reflect thin Liquidity and attention on the pending merger rather than new information.

The Vesicor Transaction

Black Hawk is a blank-check company, also known as a special purpose acquisition company. Its units consist of one Class A ordinary share and one-fifth of one right. A regulatory filing says it signed a business combination agreement with Vesicor Therapeutics, Inc. on April 26, 2025.

Vesicor is a California corporation developing a single product candidate, ecm-RV/p53. The agreed equity value is USD 70,000,000. A proxy statement dated September 21, 2026 set an extraordinary general meeting for October 13, 2026, and this review did not find a published outcome of that vote.

Trust Account and Share Structure

At an extension meeting on July 8, 2025, holders redeemed 4,775,923 shares for about USD 51.0 million, leaving 2,124,077 public shares and roughly USD 22.7 million in trust before taxes and deferred Underwriting commissions. The remaining public float is therefore small, which helps explain why trading volume is light.

A filing also states that extension payments due in November and December 2025 were made late, which it says could be challenged under the company's governing documents.

Risks

Completion of the merger depends on Shareholder approvals, the effectiveness of registration documents, listing requirements and the absence of further redemptions that would drain the trust. If the deal is not completed by December 22, 2026 the company would need a further extension or would face Liquidation of the trust.

Vesicor is a clinical-stage company with one candidate, so the combined entity's value would hinge on development results and financing rather than current revenue. The company has no operating Revenue of its own, and its main asset is the cash held in trust, which shrinks with every Redemption request that shareholders submit ahead of a vote.

What to Watch Next

Investors will look for the result of the October 13 shareholder meeting, any closing announcement for the Vesicor merger, and any notice about a further extension of the December 22, 2026 deadline.

Redemption levels and any Nasdaq communication about listing standards are other items to track. Because the float is small, price swings in blank-check shares can be sharp and are not always tied to company news, so each filing is worth reading in full.